Drug guidance
Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
Condition
Cancer
Gastrointestinal tract
1 September 2023
Published on 17 Jul 2023
Last Updated on 01 Sep 2023
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended trastuzumab deruxtecan (T-DXd) for inclusion on the MOH List of Subsidised Drugs for treating human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have received two or more prior therapies. The decision was based on the unfavourable cost-effectiveness of T-DXd at the price proposed by the company compared with chemotherapy.
Clinical indication, subsidy class and MediShield Life claim limit for T-DXd are provided in the Annex.